Background: CD36, known as a scavenger receptor, is a transmembrane glycoprotein expressed on monocytes, platelets and endothelial cells, recognizes multiple ligands, including phosphatidylserine, and regulates atherogenesis and thrombosis. The objective of this study is to investigate the possible involvement of CD36 in the pathophysiology of thrombosis in patients with antiphospholipid syndrome (APS). Methods: First, rs3765187, a missense mutation linked to CD36 deficiency, was investigated by TaqMan polymerase chain reaction (PCR) genotyping method in 819 Japanese, including 132 patients with APS, 265 with systemic lupus erythematosus (SLE) in the absence of APS, and 422 healthy subjects. Then, the involvement of CD36 in antiphospholipid antibody (aPL)-induced tissue factor (TF) expression was examined using CD36-null mice or anti-CD36. Purified IgG from patients with APS and a monoclonal phosphatidylserine-dependent antiprothrombin antibody were used in these experiments. TF expression was tested by real-time PCR and flow cytometry. Results: Minor allele carrier of rs3765187 was less frequent in patients with APS (3.8% p ¼ 0.032), but not in patients with SLE in the absence of APS (7.9% p ¼ 0.32), compared with healthy subjects (10.2%). The aPL-induced TF expression was significantly suppressed on peritoneal macrophages from CD36-null mice compared to wild type and significantly inhibited by anti-CD36 on human monocytes. Conclusions: The gene mutation linked to CD36 deficiency was less frequent in patients with APS. The deficient or suppressed CD36 function significantly reduced aPL-induced TF expression in vitro. Taken together, in a susceptible background CD36 scavenger receptor function may be involved in the thrombotic pathophysiology in patients with APS. Lupus (2013) 22, 761-771. Antiphospholipid syndrome and CD36 M Kato et al. P value and OR (95% CI) for each group were obtained by comparison with healthy subjects. OR (95% CI): odds ratio (95% confidence interval); UTR: untranslated region; APS: antiphospholipid syndrome; SLE: systemic lupus erythematosus. Antiphospholipid syndrome and CD36 M Kato et al.
Introduction
Antiphospholipid syndrome (APS) is an autoimmune disorder in which vascular thrombosis or pregnant morbidity occurs in patients having persistent laboratory evidence of antiphospholipid antibodies (aPL). It correlates with a poor prognosis or impaired activity of daily living for a high relapse rate of thrombosis. 1 Pathogenic aPL contains b2 glycoprotein I-dependent anticardiolipin antibodies (aCL/ b2GPI) and phosphatidylserine-dependent antiprothrombin antibodies (aPS/PT). 2, 3 Both antibodies recognize epitopes on the phospholipid-binding proteins (b2GPI or prothrombin) interacting with negatively charged phospholipids, such as cardiolipin and phosphatidylserine. It is commonly believed that these epitopes express only when the phospholipid-binding proteins bind with anionic phospholipids. 4 In the 1990s, the function of phospholipid-binding protein was extensively studied based on the hypothesis that the interaction of aPL with their antigens impairs their anti-or procoagulant activities. However, the activation of procoagulant cells (monocyte, endothelial cell and platelet) through the binding of phospholipid-binding protein and aPL has been the focus of investigations during the last decade. 1 Tissue factor (TF) upregulation has been advocated as one of the most important mechanisms in the pathogenesis of APS. Monocytes and endothelial cells treated with aPL demonstrate upregulation of TF expression and function, which is accompanied by an increase in interleukin (IL)-6 or other proinflammatory substances. 5, 6 Enhanced TF expression has been observed in healthy monocytes incubated with polyclonal or monoclonal aPL. 6 The activation of nuclear factor-kB (NF-kB) and p38 mitogen-activated protein kinase (MAPK) has been recognized as participating in this process as intracellular signaling pathways. 7, 8 However, cell surface receptor participation in this process is still controversial, and a number of candidates have been reported, including annexin A2, apolipoprotein E receptor 2', glycoprotein Iba, low-density lipoprotein (LDL) receptor-related protein, megalin, toll-like receptor (TLR)2, TLR4, very-low-density lipoprotein, P-selectin glycoprotein ligand-1 and integrin a5b1. [9] [10] [11] [12] [13] [14] [15] [16] CD36, known as a member of class B scavenger receptors, is an 88-kDa transmembrane glycoprotein expressed on monocytes, macrophages, platelets and capillary endothelial cells, residing in lipid raft domains. 17, 18 CD36 recognizes multiple ligands, including anionic phospholipids, oxidized LDL, long-chain fatty acid, collagen, thrombospondin-1 and malaria-infected erythrocytes and plays a role as a mediator of multiple functions including inflammation, atherogenesis and thrombosis through the activation of p38 and JNK MAPK and NF-kB. 18, 19 Human CD36 deficiency was first described in 1989 in subjects refractory to human leukocyte antigen (HLA)-matched platelet transfusions 20 and is found in 4% to 10% of Asian or African populations. [21] [22] [23] It is divided into two subgroups: In type I deficiency, neither monocyte nor platelet expresses CD36, while in type II deficiency monocyte CD36 is expressed in the absence of platelet CD36. 24 There are three major polymorphisms on the exons of CD36 gene: a missense mutation linked to human CD36 deficiency in the Japanese population (rs3765187, C478T, Pro90Ser), 21 a nonsense mutation linked to human CD36 deficiency in the African population (rs3211938, T1264G), 25 and a mutation on the 5' untranslated region (rs1049654) whose clinical significance is unknown. Some clinical phenotypes of CD36 deficiency have been reported, including hypertrophic cardiomyopathy, hypertension and dyslipidemia. [26] [27] [28] The phenotypes of CD36 knock-out (KO) mice have been reported to be protective for atherosclerosis, thrombosis and inflammation, but susceptible to infection. 19, [29] [30] [31] Considering the distribution, ligands and function of CD36, we hypothesized that CD36 is involved in the pathogenesis of APS as one of the surface receptors on procoagulant cells, and thus performed a genetic and molecular-biologic investigation.
Material and methods

Patients
A total of 819 Japanese subjects, including 132 patients with APS, 265 with systemic lupus erythematosus (SLE) in the absence of APS and 422 healthy subjects, were enrolled. All the patients fulfilled the Sydney-revised Sapporo criteria of APS 32 and/or the American College of Rheumatology classification criteria of SLE. 33 Profiles of the patients with APS are shown in Table 1 . This study was performed in accordance with the Declaration of Helsinki and the Principles of Good Clinical Practice. Approval was obtained from the local ethics committee and informed consent was obtained from each study subject before enrollment.
Determination of aPL
Two clotting tests were performed for lupus anticoagulant (LA) determination, using a semiautomated hemostasis analyzer (STart 4; Diagnostica Stago, Asnie`res-sur-Seine, France) according to the guidelines recommended by the Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. 34 For measurement of the activated partial thromboplastin time (APTT), a sensitive reagent with a low phospholipid concentration (test PTT-LA; Diagnostica Stago) was used for screening, and the results were confirmed with the use of a StaClot LA kit (Diagnostica Stago). The dilute Russell's viper venom time (dRVVT) was screened for and confirmed by use of a Gradipore LAC test (Gradipore, Sydney, New South Wales, Australia). LA was considered positive when at least one of these tests confirmed its presence. Immunoglobulin (Ig)G and IgM aCL were measured according to a standard aCL enzyme-linked immunosorbent assay (ELISA), as described elsewhere. 35 IgG and IgM ab2GPI were determined by ELISA method as previously reported. 36 Purified human b2GPI was purchased from Yamasa Corp. (Tokyo, Japan). Irradiated microtiter plates, Maxisorp (Nunc, Denmark) were coated with 4 mg/ml of purified b2GPI in phosphate-buffered saline (PBS) at 4 C and washed twice with PBS. To avoid nonspecific binding of proteins, wells were blocked with 150 ml of 3% gelatin (BDH Chemicals Ltd, Poole, UK). After three washes with PBS containing 0.05% Tween 20 (Sigma-Aldrich, St. Louis, MO, USA) (PBS-Tween), 50 ml of serum diluted with PBS containing 1% bovine serum albumin (Sigma-Aldrich) (PBS-1% BSA) in 1:50 were added in duplicate. Plates were incubated for one hour at room temperature and washed three times with PBS-Tween. Fifty microliters per well of the appropriate dilution of alkaline phosphataseconjugated goat anti-human IgG and IgM (Sigma-Aldrich) in PBS-1% BSA was added. After one hour of incubation at room temperature and after four washes in PBS-Tween, 100 ml/well of 1 mg/ml p-nitrophenylphosphate disodium (Sigma-Aldrich) in 1 M diethanolamine buffer (pH 9.8) were added. Following color development, optical density at 405 nm was measured by a Multiskan ascent plate reader (Thermo Electron Corporation, Waltham, MA, USA). Normal ranges of IgG (> 2.2 U/ml) and IgM (> 6.0 U/ml) ab2GPI with cut-off values of 99th percentile were previously established using nonpregnant 132 healthy controls.
IgG and IgM aPS/PT were detected by ELISA, as previously described. 37 Briefly, nonirradiated microtiter plates (Sumilon Type S; Sumitomo Bakelite, Tokyo, Japan) were coated with 30 ml of a 50mg/ml preparation of phosphatidylserine (Sigma-Aldrich) and dried overnight at 4 C. To avoid nonspecific binding of proteins, the wells were blocked with 150 l of Tris-buffered saline (TBS) containing 1% fatty acid-free BSA (catalog no. A6003; Sigma-Aldrich) and 5 mM CaCl 2 (BSA-CaCl 2 ). After three washes in TBS containing 0.05% Tween 20 (Sigma-Aldrich) and 5 mM CaCl 2 (TBS-Tween-CaCl 2 ), 50 ml of a 10mg/ml preparation of human prothrombin (Diagnostica Stago) in BSA-CaCl 2 was added to half of the wells in the plates, and the same volume of BSA-CaCl 2 alone (as sample blank) was added to the other half. After one hour of incubation at 37 C, the plates were washed, and 50 ml of serum diluted 1:100 in BSA-CaCl 2 was added to duplicate wells. Plates were incubated for one hour at room temperature, and alkaline phosphatase-conjugated goat anti-human IgG or IgM and substrate were added. The aPS/PT antibody titer of each sample was derived from the standard curve according to dilutions of the positive control.
Genotyping CD36 gene polymorphisms were investigated in this population using the TaqMan polymerase chain reaction (PCR) genotyping method on a 7500 Fast Real-Time PCR System Õ (Applied Biosystems, Foster City, CA, USA). Genomic DNA samples were extracted from peripheral blood. Related risk for having APS or SLE was approximated by odds ratio (OR).
Materials
Animal studies were reviewed and approved by Hokkaido University Institutional Animal Care and Use Committee. CD36KO mice were kindly donated by Dr Yamashita, Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Japan. 38 FA6-152, a mouse monoclonal anti-human CD36 antibody (aCD36) with the CD36 signal blocking property, was purchased (Abcam, Cambridge, UK). 39 A mouse monoclonal aPS/PT with LA activity, 231D, was prepared as described previously. 3 Purified total IgG from APS patients either aCLor aPS/PT-positive (Pt-aCL and Pt-aPS/PT, respectively) or healthy donors (Healthy-IgG) were prepared using MelonTM Gel IgG Purification Kit (Takara Bio, Ohtsu, Japan). Purity of IgG was checked by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Pt-aCL and Pt-aPS/PT were confirmed to have aPL titers by ELISA as described above. Clinical profiles of the patients whose IgG was purified are shown in Table 2 . All antibodies were confirmed not to be contaminated with lipopolysaccharide (LPS) using Limulus ES-II Single Test Õ (Wako, Osaka, Japan).
Mouse peritoneal macrophage (MPM) stimulation assay
At three days after intraperitoneal injection of 2 ml 10% proteose peptone (Becton Drive, Franklin Lakes, NJ, USA), MPM were harvested from 8 -to 12-week-old female CD36KO or C57BL/6 J wildtype (WT) mice. MPMs were suspended in Dulbecco's modified Eagle medium (DMEM) (Sigma-Aldrich, St. Louis, MO, USA) supplemented with 10% fetal calf serum (Invitrogen, Carlsbad, CA, USA) containing penicillin and streptomycin and their concentration adjusted to 1 Â 10 6 cells/ml. MPMs were then treated with aPL (300 mg/ml Pt-aCL, 300 mg/ml Pt-aPS/PT or 10 mg/ml 231D) and incubated for four hours at 37 C 5% CO 2 . Pt-aPS/PT and 231D were used in the presence of 2.5 mM CaCl 2 and 10 mg/ml human prothrombin (Diagnostica Stago). 3 Equal concentrations of Healthy-IgG or mouse IgG1k isotype control (Becton Drive) was used as a negative control and 600 ng/ml LPS (Sigma-Aldrich) was used as a positive control. Data were obtained by five or more independent experiments.
Human peripheral blood mononuclear cell (PBMC) stimulation assay
Venous blood was collected in heparin from a healthy donor. Human PBMC were isolated on Ficoll-Paque plus Õ gradient centrifugation (Amersham Biosciences, Piscataway, NJ, USA). Human PBMCs were suspended in DMEM supplemented with 10% fetal calf serum containing penicillin and streptomycin and their concentration adjusted to 1 Â 10 6 cells/ml. Human PBMC were then treated with aPL (200 mg/ml Pt-aCL, 200 mg/ ml Pt-aPS/PT or 2 mg/ml 231D) in the presence or absence of 1 mg/ml aCD36 and incubated for four hours at 37 C 5% CO 2 . Pt-aPS/PT and 231D were used in the presence of 2.5 mM CaCl 2 and 10 mg/ml human prothrombin. Equal concentrations of Healthy-IgG or mouse IgG1k isotype control was used as a negative control and 1 ng/ml LPS was used as a positive control. Data were obtained by three or more independent experiments. The healthy donor was confirmed to have CD36 on both monocytes and platelets by analysis by flow cytometry before the experiments were performed (data not shown).
RNA extraction and quantitative TaqMan real-time PCR
Total RNA was isolated from MPM or human PBMC using RNeasy Mini Kit Õ (Qiagen, Valencia, CA, USA) and reverse-transcribed with Super ScriptTM First-Strand Synthesis System for RT-PCR (Invitrogen). Quantitative analysis of TF or IL-6 gene expression was performed by real-time PCR using 7500 Fast Real-Time PCR System Õ and gene-specific TaqMan Minor Groove Binder probes (Mm00438855m1, Hs01076032m1, Mm004461 90m1 and Hs00174131m1; Applied Biosystems). The level of the TF or IL-6 transcript was normalized to that of the glyceraldehyde-3-phosphate dehydrogenase. Relative quantification was performed using the comparable cycle threshold method.
Monocyte TF antigen expression by flow cytometry
Surface TF expression on human monocytes, treated with aPL as described above, was evaluated by flow cytometry with a direct doublecolor immunofluorescence technique. Resuspended human PBMC were incubated with phycoerythrinconjugated mouse monoclonal anti-human CD14 (Beckman Coulter, Brea, CA, USA) and with fluorescein-conjugated mouse monoclonal anti-human Gating was accomplished using size, complexity and phycoerythrin gates to define the monocyte population of PBMC.
Statistical analysis
Statistical evaluation was performed by chi square test, Fisher's exact test or Student's t test, as appropriate. P values less than 0.05 were considered significant.
Results
Allele frequencies of CD36 gene polymorphisms
Allele frequencies of the two CD36 gene polymorphisms were compared among three groups: healthy subjects, APS and SLE in the absence of APS. Minor allele carrier of rs3765187 (C478T Pro90Ser), a missense mutation linked to human CD36 deficiency, was significantly less frequent in APS (3.8%) compared to healthy subjects (10.2%). In contrast, rs3765187 minor allele carrier was as frequent in SLE in the absence of APS as it was in healthy subjects. There was no significant difference in allele frequency of rs1049654, a mutation on the 5' untranslated region, among those groups ( Table 3) .
Expressions of TF and IL-6 on MPM induced by aPL
Expressions of TF and IL-6 were analyzed on MPM from WT or CD36KO mice cultured with each aPL and its antigen. All three aPL used in this experiment, Pt-aCL, Pt-aPS/PT and 231D, induced TF mRNA expression in MPM up to 10fold. The aPL-induced TF mRNA expression was significantly reduced in MPM from CD36KO mice compared to MPM from WT mice (Figure 1(a) ). Those three aPL induced IL-6 mRNA expression in MPM up to 60-fold. The aPL-induced IL-6 mRNA expression was significantly reduced in MPM from CD36KO mice compared to MPM from WT mice (Figure 1(b) ). TF: tissue factor; IL-6: interleukin 6; aPS/PT: phosphatidylserine-dependent antiprothrombin antibodies; IgG: immunoglobulin G; MPM: mouse peritoneal macrophage; WT: wild-type; aPL: antiphospholipid antibodies; Pt-aCL: purified total IgG from aCL-positive APS patient; Pt-aPS/ PT: purified total IgG from aPS/PT-positive APS patient; LPS: lipopolysaccharide.
Expressions of TF and IL-6 on human PBMC induced by aPL
Expressions of TF and IL-6 were analyzed on human PBMC from a healthy donor cultured with each aPL and its antigen. All three aPL used in this experiment, Pt-aCL, Pt-aPS/PT and 231D, induced TF mRNA expression in human PBMC from a healthy donor up to 16-fold. The aCD36 significantly reduced aPL-induced TF mRNA expression in human PBMC. In contrast, equal concentration of mouse IgG1k isotype control did not reduce it (Figure 2(a) ). Those three aPL induced IL-6 mRNA expression in human PBMC from a healthy donor up to 40-fold. The aCD36 significantly reduced aPL-induced IL-6 mRNA expression in human PBMC. In contrast, equal concentration of the mouse IgG1k isotype control did not reduce it (Figure 2(b) ). We next performed analysis by flow cytometry to confirm the TF expression on monocytes. Those three aPL also induced surface TF expression on human CD14-positive cells from a healthy donor. The aCD36 reduced aPL-induced surface TF expression on human CD14-positive cells. In contrast, equal concentration of the mouse IgG1k isotype control did not reduce it (Figure 3) .
aCD36: anti-CD36 antibody; TF: tissue factor; IL-6: interleukin 6; IgG: immunoglobulin G; aPS/ PT: phosphatidylserine-dependent antiprothrombin antibodies; PBMC: human peripheral blood mononuclear cells; Pt-aCL: purified total IgG from aCL-positive APS patient; Pt-aPS/ 
Discussion
In this study, we demonstrated that the gene mutation linked to human CD36 deficiency was less frequent in patients with APS and that the deficient or suppressed CD36 function significantly reduced aPL-induced TF/IL-6 expressions in vitro. CD36 may be involved in the thrombotic pathophysiology in patients with APS. A few patients with APS, however, had the gene mutation linked to human CD36 deficiency and knocking out CD36 did not lead to complete diminuendo of aPLinduced TF expression. Taken together, CD36 may be one of the cell surface receptors involved in the pathogenesis of APS.
CD36 resides in lipid raft domains and interacts with a variety of membrane receptors, such as integrin a3b1, a6b1, tetraspanins and TLRs. The latest was elegantly demonstrated on macrophage in studies showing cooperation between CD36 and TLR2 or TLR6 in the recognition and response to Table 2 ), which induced the highest TF expression in the response of mouse peritoneal macrophages. aCD36: anti-CD36 antibody; MFI: mean fluorescence intensity; TF: tissue factor; IgG: immunoglobulin G; aPL: antiphospholipid antibodies; Pt-aCL: purified total IgG from aCL-positive APS patient; Pt-aPS/PT: purified total IgG from aPS/PT-positive APS patient; APS: antiphospholipid syndrome; LPS: lipopolysaccharide.
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bacteria cell wall components, such as
Staphylococcus-derived lipoteichoic acid and diacylated lipoproteins. 31, 40 Several CD36 functions, including microglial phagocytosis and platelet response, require integrin a3b1, a6b1 or tetraspanins. 41, 42 The mechanism of the thrombotic tendency in APS has been clarified at the molecular level by many investigations. TF upregulation on procoagulant cells is considered to be the most important procedure in the pathogenesis of APS. Elevation of plasma TF level and upregulation of TF expression on monocytes, which was accompanied by an increase in TF pathway inhibitor, were found in patients with APS. 6, 43 Elevated plasma level of soluble fibrin and that of D-dimer, which reflects thrombin generation and fibrin turnover, were also found, presumably related to the ''chronic'' TF upregulation and activation of extrinsic coagulation pathway. 3 In in vitro studies, monocytes and endothelial cells treated with aPL demonstrated upregulation of TF and adhesion molecules. 5, 6 NF-kB and p38MAPK were shown to participate in the procoagulant cell activation as intracellular signaling pathways. We 7 and others 8 showed that p38 MAPK protein was phosphorylated with NF-kB activation by aCL/b2GPI treatment and that SB203580, a specific p38 MAPK inhibitor, decreased the aCL/b2GPI-induced TF mRNA expression.
A number of candidates for the cell surface receptor involved in this pathogenesis have been reported. [9] [10] [11] [12] [13] [14] [15] [16] Sorice et al. 44 showed the lipid raft recruitment of b2GPI and TLR-4 in human monocytes when interacting with aCL/b2GPI, suggesting that the procoagulant cell activation by aPL may involve the recruitment of cell surface receptors on lipid rafts. Given that CD36 resides in lipid raft domains and interacts with a variety of membrane receptors, our data support those findings and suggest that CD36 interacts with other b2GPI/ prothrombin receptors involved in the pathogenesis of APS.
In clinical practice, treatment of APS has focused on utilizing antithrombotic medications such as warfarin, heparin or aspirin. Despite longterm antithrombotic medications, thrombosis can recur in patients with APS and antithrombotic medications can be associated with bleeding. 45 Given that thrombotic events occur only occasionally in patients with APS, aPL increase the thrombophilic threshold as the ''first hit,'' and then clotting takes place only when a ''second hit'' exists, such as an infection or a surgical procedure. 46 Current antithrombotic medications in APS are directed to modulate the final event or ''second hit.'' However, treatments that modulate the ''first hit'' would be more beneficial and potentially less harmful than current antithrombotic medications.
Our results suggest that inhibition or reduction of CD36 can be one of the options for the prophylaxis against thrombosis in patients with APS. Treatment targeting CD36 might be safe because heredity CD36 deficiency is not associated with serious clinical manifestations including bleeding disorders, suggesting that CD36 is a strong potential target of the treatment of patients with APS. CD36 expression is regulated by multiple agents on monocytes. It can be upregulated by adhesion, macrophage-colony stimulating factor, granulocyte/ macrophage-colony stimulating factor, native and modified LDL, cellular cholesterol, IL-4 and high glucose conditions, while downregulated by corticosteroids, transforming growth factor-b1, high-density lipoprotein and LPS. 47 Statin and cilostazol, medical agents having some pleiotropic effects, were reported to downregulate CD36 expression on monocytes. 48, 49 These agents might have implications for treatment of APS.
Given that CD36 deficiency may be protective for developing APS, we suspected some specific clinical features in patients with APS who have the minor allele rs3765187. In our study, one patient with APS who carried the homozygous minor allele of rs3765187 exhibited central retinal vein occlusion as a sole APS manifestation and had aCL as a sole aPL; on the other hand, four heterozygous carriers exhibited typical APS manifestations and serological abnormalities ( Table 4) . Further studies will better delineate the correlation between minor allele of rs3765187 and severity of APS manifestations.
In conclusion, both genetically and biologically, our results suggest that in a susceptible background CD36 scavenger receptor function may be involved in the thrombotic pathophysiology in patients with APS.
